Compugen Ltd. · NASDAQ:CGEN
Compugen — Investor Presentation (June 2016)
47 slides from Compugen's investor presentation, June 2016
Slide 1: Predictive Discovery of First-in-Class Biologics
PREDICTIVE DISCOVERY OF FIRST-IN-CLASS BIOLOGICS Primary focus on immuno-oncology Corporate Overview June 2016 www.cgen.com www.cgen.com 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” and “intends,”
Slide 3: Company Overview
Company Overview Mission Discover high value novel targets and develop first-in-class biologics for unmet medical needs Leadership in Predictive Drug Discovery Broadly applicable discovery infrastructure Business Model Selectively partner first-in-class biologics at various stages under revenu
Slide 4: Company Fact Sheet
Company Fact Sheet Strong Intellectual Property Landscape Proprietary algorithms and computational biology platforms 61 issued and allowed patents, 137 pending patent applications, in all major countries Experienced Multidisciplinary Teams ~90 employees, 70% R&D Algorithm development, co
Slide 5: Two Centers of Excellence
Two Centers of Excellence Compugen Ltd. Compugen USA, Inc. Holon, Israel South San Francisco, USA Headquarters Wholly-Owned Subsidiary Predictive Target Discovery Therapeutic mAb & Experimental Validation Research & Development 5
Slide 6: Scientific Advisory Board
Scientific Advisory Board Renowned Oncologists and Immunologists Drew Pardoll, MD, PhD (Chairman of the SAB; Director - Compugen USA, Inc.) Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the
Slide 7: Pipeline Program Focus Areas
Pipeline Program Focus Areas Multiple Novel Target Candidates for First-in-Class Opportunities Oncology Novel Novel immune checkpoint Antibody Drug Conjugate target candidates target candidates Immunology One program for autoimmune diseases based on a novel immune checkpoint target Diverse portfolio
Slide 8: B7/CD28 Immune Checkpoints for Cancer Immunotherapy
B7/CD28 Immune Checkpoints for Cancer Immunotherapy Harnessing the immune system to destroy cancer cells Breakthrough approach to cancer therapy Impressive, long-lasting clinical benefits Still, the majority of cancer patients do not respond New checkpoints, drug combinations and drug moda
Slide 9: Targeting of Immune Checkpoints Today
Targeting of Immune Checkpoints Today Crowded Competition on Same Targets PI PIII PC PIII PII PI PC ? M M PC PII PI PC PC PI PI M PI PC PC PI PII PI PC PC PC PI PC PC PI PC PC PC PC PC PC
Slide 10: From the Genome to the Clinic
From the Genome to the Clinic An Integrated Approach PREDICTIVE PIPELINE STRATEGIC PREDICTIVE DISCOVERY PROGRAM PARTNERSHIPS DISCOVERY 10
Slide 11: Pharma's Observational Path to Novel Targets
Pharma’s Observational Path to Novel Targets COLLECTION OF DISEASE KNOWN GENES / PROTEINS SAMPLES EXPERIMENTAL CHARACTERIZATION DATA ANALYSIS NOVEL TARGETS FIRST-IN-CLASS Known proteins/genes, disease-specific, assay systems limitation No learning
Slide 12: Compugen: Leaders in Predictive Biology
Compugen: Leaders in Predictive Biology Merging Computational Biology and Translational Medicine 15 YEARS OF SCIENTIFIC INFRASTRUCTURE DEVELOPMENT Broadly applicable, consists of multiple discovery platforms APPLIED TO DISCOVERY OF NOVEL DRUG TARGET FOR FIRST-IN-CLASS BIOLOGICS
Slide 13: Applying Our Predictive Approach
Applying Our Predictive Approach First Focused Discovery Program: Novel Immune Checkpoint Targets CGEN-15001T CGEN-15052 CGEN-15022 CGEN-15092 CGEN-15049 CGEN - 15029 Undisclosed Targets Partial data sources shown for illustrative purposes B7 refers to B7/CD28 13
Slide 14: Immune Checkpoint Platform
Immune Checkpoint Platform Genomic Detection Leading to Diverse Set of Novel Candidates Diversified portfolio of immuno-oncology targets CGEN candidate Shown for illustrative purpose only 14
Slide 15: From the Genome to the Clinic
From the Genome to the Clinic An Integrated Approach PREDICTIVE PIPELINE STRATEGIC PIPELINE DISCOVERY PROGRAM PARTNERSHIPS PROGRAM 15
Slide 16: Pipeline Program
Pipeline Program Novel Immune Checkpoint Target Candidates CGEN-15029 Lead drug program Shown for illustrative purpose only 16
Slide 17: CGEN-15029 mRNA is Expressed in Many Cancers
CGEN-15029 mRNA is Expressed in Many Cancers Expression in multiple cancer indications Elevated expression in kidney cancers 17
Slide 18: CGEN-15029 Expression Associated With Tumor Infiltrating Immune Cells
CGEN-15029 Expression Pattern Associated With Tumor Infiltrating Immune Cells (TILs) RNA correlation with CD8 T cells and PD-1 Confirmed TIL protein expression (Kidney Clear Cell Cancer) (Melanoma) CD8 vs 15029 PD-1 vs 15029 18
Slide 19: RNA Expression of CGEN-15029 Correlated With PD-1, TIM-3 and TIGIT
RNA Expression of CGEN-15029 Highly Correlated With PD-1, TIM-3 and TIGIT in Solid Tumors All tumors (TCGA) Melanoma (TCGA) 19
Slide 20: CGEN-15029 Expressed on Tumor Infiltrating T-cells from Melanoma Patients
CGEN-15029 Expressed on Tumor Infiltrating T-cells Derived from Melanoma Patients TIL Patient 1 TIL Patient 2 CGEN-15029 KD + anti 15029 CGEN-15029 Negative Control (hIgG2) Expression is confirmed by knockdown (siRNA)
Slide 21: CGEN-15029 Inhibits T Cell Cytotoxic Activity
CGEN-15029 Inhibits T Cell Cytotoxic Activity Inhibition of Cytotoxic T Cell Activation Cohen and Safion, Bar Ilan Univ. 21
Slide 22: CGEN-15029: Binding Partner Identified
CGEN-15029: Binding Partner Identified Binding of hCGEN-15139-Fc to HEK293 cells over expressing hCGEN-15029 Binding of ligand (CGEN-15139) to receptor (CGEN-15029) was confirmed by SPR, ELISA and FACS 22
Slide 23: COM701 Lead mAb Demonstrates High Affinity Binding
COM701 Lead mAb Demonstrates High Affinity Binding Sub-nanomolar affinity binding to T cell line 23
Slide 24: COM701 Lead mAb Potently Inhibits Receptor-Ligand Interactions
COM701 Lead mAb Potently Inhibits Receptor - Ligand Interactions Antibody binding and activity maintained following humanization Potent enhancement of T cell activation 24
Slide 25: CGEN-15029: Highest Priority mAb Program
CGEN-15029: Highest Priority mAb Program High-affinity functional blocking antibodies have been identified Lead therapeutic mAb selected – COM71 Humanization process completed Cell line development initiated Manufacturing agreement in place IND anticipated in 2017 25
Slide 26: Pipeline Program
Pipeline Program Novel Immune Checkpoint Target Candidates CGEN-15029 Lead drug program CGEN candidate Shown for illustrative purpose only 26
Slide 27: Myeloid CGEN-Candidates
Myeloid CGEN-Candidates Myeloid cells are important components of the tumor microenvironment Primarily Tumor Associated Macrophages (TAMs) and Myeloid Derived Suppressor Cells (MDSCs) TAMs and MDSCs are highly immunosuppressive and inhibit effector T and NK responses against the tumors Emerging area
Slide 28: Myeloid CGEN-Candidate
Myeloid CGEN-Candidate Low Expression in Solid Normal Tissues and Induction in Cancer CGEN-Candidate Expression Profile in CGEN-Candidate Expression Normal Tissues Normal vs. Cancer 28
Slide 29: Myeloid CGEN-Candidate: CD68 Expression
Myeloid CGEN-Candidate Induction in Cancer Correlated with Myeloid Specific Markers CD68 Expression Myeloid CGEN Candidate Expression 29
Slide 30: CGEN-Candidates Expressed in Specific Myeloid Subpopulations
CGEN-Candidates Expressed in Specific Myeloid Subpopulations Example 1 Macrophage Naïve Immune Cells Lung Tumor Subpopulations 30
Slide 31: CGEN-Candidates Expressed in Specific Myeloid Subpopulations
CGEN-Candidates Expressed in Specific Myeloid Subpopulations Example 2 Macrophage Naïve Immune Cells Lung Tumor Subpopulations 31
Slide 32: Pipeline Program
Pipeline Program Novel Immune Checkpoint Target Candidates CGEN candidate • Two partnered I/O programs • Fc-fusion for autoimmune diseases Shown for illustrative purpose only 32
Slide 33: Cell Surface Tumor Antigen Targets
Cell Surface Tumor Antigen Targets Second Focused Discovery Program: ADC Targets The goal: identify membrane proteins over-expressed on cancer but with little or no expression on normal tissues 33
Slide 34: Example: Expression Profile Analysis
Example: Expression Profile Analysis High Cancer Expression, Low Toxicity, Low Sink Potential Predictive discovery driven analysis 34
Slide 35: CGEN-15027: A Novel ADC Target
CGEN-15027: A Novel ADC Target High Expression in Ovarian and Lung Cancers Normal Ovary Ovarian Cancer Ovarian Cancer (Endometroid adenocar.) (Mucinous cystadenocar.) Normal Lung Lung Cancer Lung Cancer (Adenocarcinoma.) (Adenocarcinoma) 35
Slide 36: Antibody-Drug Conjugate Against CGEN-15027
Antibody-Drug Conjugate Against CGEN-15027 Potent Cytotoxicity in Multiple Cancer Cell Lines FACS Cytotoxicity Binding IHC Ovarian Adenocarcinoma Cell line IC50= 0.18 Liver HCC Cell line IC50= 0.078
Slide 37: CGEN-15001: Lead Program for Autoimmune Diseases
CGEN-15001: Lead Program for Autoimmune Diseases Robust Efficacy in Animal Models EAE: Multiple Sclerosis CIA: Rheumatoid Arthritis NOD: Type 1 Diabetes Rx Rx Miller and Podojil, Northwestern Univ. Williams and McNamee, Univ. of Oxford, UK Miller and Podojil, Northwestern Univ. HY Mismatch: Bone Mar
Slide 38: CGEN-15001 Differentiation and Value Proposition
CGEN-15001 Differentiation and Value Proposition Differentiating Features from Current Therapies • Restores immune balance • Inhibits pro-inflammatory and promotes anti-inflammatory cytokines • Restores the Th1/Th2/Treg balance – promotes iTreg differentiation • Induces antigen-specific immune toler
Slide 39: From the Genome to the Clinic
From the Genome to the Clinic An Integrated Approach PREDICTIVE PIPELINE STRATEGIC STRATEGIC DISCOVERY PROGRAM PARTNERSHIP PARTNERSHIPS 39
Slide 40: Strategic Alliances to Drive Value
Strategic Novel Alliances to Drive Value Targets for First-in-Class and Opportunities Commercialize The Next Wave Programs in Immuno-Oncology Multiple programs to be advanced through combination of internal development and collaborations Enter collaborations at both early and later stage of deve
Slide 41: Bayer Novel Partnership
BayerNovel Partnership Targets for First-in-Class Opportunities Strategic TheCollaboration Next WavetoinDevelop Cancer Immunotherapies Immuno-Oncology Early stage collaboration and license agreement for antibody-based cancer therapeutics Collaboration includes two novel immune checkpoint target ca
Slide 42: Bayer Novel Partnership: Current Status
BayerNovel Partnership: Current Status Targets for First-in-Class Opportunities The Next Next Targets Wave in Immuno-Oncology for Anti-Tumor Immunity • CGEN-15001T and CGEN-15022: Two novel immune checkpoints • Each presents a distinctive differentiation profile compared to known checkpoints • Targe
Slide 43: Collaboration with Johns Hopkins School of Medicine
Collaboration with Johns Hopkins School of Medicine Multi-Year Immuno-Oncology Collaboration • Focused on Compugen’s novel immune checkpoint target candidates • Led by Johns Hopkins Professors Drew Pardoll and Charles Drake • Supports and accelerates translation to the clinic • Target characterizati
Slide 44: From the Genome to the Clinic: Drivers and Anticipated Milestones
From the Genome to the Clinic Drivers and Anticipated Milestones hPOC in clinical trials: Partnered and un-partnered programs Advancing internal programs First IND anticipated in 2017 for CGEN-15029 Multiple programs in various stages of target validation or antibody discovery Continuing pro
Slide 45: Financial Status
Financial Status • Strong Financial position • Cash balance ~$81 million (March 31, 2016) • No Debt • Gross Cash Expenditures* • Forecast 2016 ~$31-$33 million • Market Capitalization • ~$350 million (May 2016) • NASDAQ (CGEN); Indices – NBI (Nasdaq Biotech Index) • TASE (CGEN.TA); Indices - TA-75,
Slide 46: Compugen's Key Differentiators
Compugen’s Key Differentiators Focus on First-in-Class Therapeutics Pipeline Program based on novel targets Significant opportunity for first-in-class drugs Broad IP landscape Reliance on Predictive Discovery Discover multiple target candidates for each discovery program Predict new li
Slide 47: Predictive Discovery of First-in-Class Biologics
PREDICTIVE DISCOVERY OF FIRST-IN-CLASS BIOLOGICS Primary focus on immuno-oncology Corporate Overview June 2016 www.cgen.com www.cgen.com